Triomics vs xCures (2026)
Both read oncology records that were never designed to be read by software, and they solve different halves of that. Triomics reasons over the chart the cancer centre already has, with an oncology tuned platform, peer reviewed validation in a recognised journal, and every match traced back to the pathology and biomarker that produced it, delivered where the team already works. xCures goes and gets the chart in the first place, retrieving across local, state and national exchanges to assemble a longitudinal history, publishing how each of its extractors is validated and stating plainly that it acts as its customer's business associate. A cancer centre whose patients arrive with care delivered elsewhere has the xCures problem. One whose records are complete and unread has the Triomics problem. Most large centres have both.
- The output lands where the work happens, with the deepest integration position in this category, so eligibility reasoning reaches the oncology team inside their existing workflow rather than in a separate screening tool.
- Peer reviewed validation published in a recognised digital medicine journal, which is the strongest evidence position in the clinical trials category.
- Every match is traced back to the pathology, biomarker and note that produced it, so a coordinator can check the reasoning rather than trusting a score.
- Retrieval is the core competency: connectivity across local, state and national exchanges to assemble a longitudinal history from records that were never in one place.
- It states without qualification that it operates as its customer's business associate, which is a stronger and rarer posture than the assertions common in this category.
- The model disclosure is among the most complete in the index, naming distinct extraction approaches and publishing how each extractor is validated rather than describing a proprietary engine.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Triomics and xCures are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Triomics | xCures |
|---|---|---|
| Primary category | Clinical Trials AI | Clinical Decision Support |
| Founded | 2021 | 2018 |
| Headquarters | San Francisco, California | Oakland, California |
| Website | triomics.com | xcures.com |
Side by Side
Each record in one paragraph
Written to be quoted whole. Each paragraph states what the AI Health Index verified about the vendor, with the caveats attached. Generated from this pair’s live capability grades, so it moves when a grade moves.
The AI Health Index awards Triomics its top capability grade on several axes, including AI Centrality, Autonomy and Oversight Model and Model and Technology Transparency. Set against xCures, Triomics grades higher on FDA and Regulatory Status and Setting and Specialty Coverage. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
The AI Health Index awards xCures its top capability grade on several axes, including AI Centrality, Autonomy and Oversight Model and Model and Technology Transparency. Set against Triomics, xCures grades higher on HIPAA and BAA Posture and Security Certifications and Trust Center. Grades reflect evidence the AI Health Index could verify at the last review, so a low grade records disclosure the vendor has not published rather than a capability it has been shown to lack.
Source: AI Health Index, August 2026
Questions buyers ask
Should we choose Triomics or xCures?
On the axes where the AI Health Index separates them, Triomics grades higher on FDA and Regulatory Status and Setting and Specialty Coverage, and xCures grades higher on HIPAA and BAA Posture and Security Certifications and Trust Center. Neither leads on the greater share of scored axes, so the decision turns on which constraint is binding rather than on an overall winner.
Where do Triomics and xCures differ most?
The widest separation the AI Health Index records between Triomics and xCures is on FDA and Regulatory Status, where Triomics grades B and xCures grades C. That axis sits in the Regulatory and Compliance group, so it should carry the most weight for a buyer whose binding constraint is where regulatory exposure sits and who carries it.
Where do Triomics and xCures grade the same?
The AI Health Index grades Triomics and xCures the same on several axes, including AI Centrality, Autonomy and Oversight Model and Model and Technology Transparency. Neither holds an advantage the index can evidence on those axes, so they should not carry weight in a selection between these two.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
These products sit at adjacent layers and are often complementary: one retrieves and structures records the institution does not hold, the other reasons over the chart it does. Neither publishes pricing. Triomics publishes no security attestation or trust centre. Both should be asked the number this category never publishes, the false negative rate for eligibility screening, since a patient who was eligible and never surfaced is invisible in every metric either vendor reports. Trial matching also carries a documentation bias worth naming: patients with thin or fragmented records match less often regardless of eligibility.